Resiniferatoxin - Sorrento Therapeutics

Drug Profile

Resiniferatoxin - Sorrento Therapeutics

Alternative Names: MCP-101; RTX

Latest Information Update: 12 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Institutes of Health (USA)
  • Developer ICOS Corporation; Mt Cook Pharma; National Institutes of Health (USA); Sorrento Therapeutics
  • Class Analgesics; Small molecules
  • Mechanism of Action TRPV1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cancer pain
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Cancer pain
  • Discontinued Interstitial cystitis; Overactive bladder; Rhinitis

Most Recent Events

  • 29 Nov 2017 Sorrento and National Institutes of Health (USA) re-initiates enrolment in a phase I/II trial for Cancer pain in USA (Intrathecal) (NCT00804154)
  • 01 Aug 2017 Phase-I clinical trials in Cancer pain in USA (Epidural) (NCT03226574)
  • 30 Jun 2017 Sorrento Therapeutics plans a phase II trial for Cancer pain in late 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top